Analyst Price Targets — WGS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 29, 2026 11:01 am | — | Guggenheim | $74.00 | $69.82 | TheFly | GeneDx price target raised to $74 from $70 at Guggenheim |
| June 23, 2026 10:57 am | David Westenberg | Piper Sandler | $63.00 | $55.42 | TheFly | GeneDx price target raised to $63 from $50 at Piper Sandler |
| May 5, 2026 12:09 pm | Bill Bonello | Craig-Hallum | $85.00 | $35.59 | TheFly | GeneDx price target lowered to $85 from $153 at Craig-Hallum |
| May 5, 2026 11:35 am | — | BTIG | $90.00 | $67.93 | TheFly | GeneDx price target lowered to $90 from $170 at BTIG, removed from Top Picks |
| May 5, 2026 11:21 am | — | Guggenheim | $70.00 | $67.93 | TheFly | GeneDx price target lowered to $70 from $100 at Guggenheim |
| May 5, 2026 10:46 am | Kyle Mikson | Canaccord Genuity | $75.00 | $67.93 | TheFly | GeneDx price target lowered to $75 from $100 at Canaccord |
| May 5, 2026 10:20 am | Brandon Couillard | Wells Fargo | $75.00 | $67.93 | TheFly | GeneDx price target lowered to $75 from $155 at Wells Fargo |
| April 20, 2026 1:08 pm | — | Canaccord Genuity | $100.00 | $67.72 | TheFly | GeneDx price target raised to $100 from $70 at Canaccord |
| February 24, 2026 12:45 pm | Mark Massaro | BTIG | $170.00 | $87.08 | TheFly | GeneDx price target lowered to $170 from $200 at BTIG |
| February 24, 2026 11:41 am | David Westenberg | Piper Sandler | $130.00 | $87.08 | TheFly | GeneDx price target lowered to $130 from $160 at Piper Sandler |
Latest News for WGS
NEW YORK, July 17, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plaintiff deadline. So What: If you purchased GeneDx common stock during the Class Period you may be entitled to compensation without…
/PRNewswire/ -- - Kahn Swick and Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”), of the important August 3, 2026 lead plaintiff deadline.
New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 17, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) ("GeneDx" or the "Company"), if…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for WGS.
U.S. House Trading
No House trades found for WGS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.